Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022120375 - POLYPEPTIDES FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION

Publication Number WO/2022/120375
Publication Date 09.06.2022
International Application No. PCT/US2021/072723
International Filing Date 03.12.2021
IPC
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
G01N 33/569 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
A61K 39/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
CPC
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Applicants
  • THE UNIVERSITY OF CHICAGO [US]/[US]
  • WISCONSIN ALUMNI RESEARCH FOUNDATION [US]/[US]
Inventors
  • WILSON, Patrick
  • DUGAN, Haley
  • STAMPER, Christopher
  • KAWAOKA, Yoshihiro
  • HALFMANN, Peter
Agents
  • STELLMAN, Laurie, Friesenhahn
Priority Data
63/121,38404.12.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) POLYPEPTIDES FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION
(FR) POLYPEPTIDES DE DÉTECTION ET DE TRAITEMENT D'INFECTION À CORONAVIRUS
Abstract
(EN) To address the need in the art, the inventors have comprehensively characterized the SARS-CoV-2-specific B cell repertoire in convalescent COVID-19 patients and generated mAbs against the spike, ORF8, and NP proteins. Together, the inventors' data reveal key insight into antigen specificity and B cell subset distribution upon SARS-CoV-2 infection in the context of age, sex, and disease severity. Aspects of the disclosure relate to novel antibody and antigen binding fragments. Further aspects relate to polypeptides comprising the antigen binding fragment(s) of the disclosure, and compositions comprising the polypeptides, antibodies, and/or antigen binding fragments of the disclosure. Also described are nucleic acids encoding an antibody or antigen binding fragment of the disclosure.
(FR) Pour répondre au besoin de l'état de la technique, les inventeurs ont complètement caractérisé le répertoire des lymphocytes B spécifiques au SARS-CoV-2 chez des patients atteints de la COVID-19 convalescents et des mAb générés contre les protéines de spicule, ORF8, et NP. Conjointement, les données des inventeurs ont révélé un aperçu clé en une distribution de sous-ensemble de spécificité antigénique et de lymphocytes B lors d'une infection à SARS-CoV-2 dans le contexte d'âge, de sexe et de gravité de maladie. Selon certains aspects, la divulgation concerne un nouvel anticorps et des fragments de liaison à l'antigène. D'autres aspects concernent des polypeptides comprenant le ou les fragments de liaison à l'antigène selon la divulgation, et des compositions comprenant les polypeptides, les anticorps et/ou les fragments de liaison à l'antigène selon la divulgation. La divulgation concerne également des acides nucléiques codant pour un anticorps ou un fragment de liaison à l'antigène selon la divulgation.
Latest bibliographic data on file with the International Bureau